ValueWalk |
Dementia Drug Developer Axovant Climbs After $315M IPO
ABC News The company is preparing to start late-stage trials of RVT-101 as a once-per-day treatment for dementia caused by Alzheimer's disease and also wants to study it as a treatment for other types of dementia. Axovant says that in one clinical study … Did Glaxo's scientists miss a blockbuster Alzheimer's drug? |